You need JavaScript to view this

Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation

Journal Article:

Abstract

DNA-spermidine (DA-51), which has been originally developed by Dr. Sekiguchi et al. as a protective agent against radiation-induced leukopenia, was submitted to clinical trial by the double blind test. The protective effect against radiation-induced leukopenia and side effect of DA-51 were compared with those of Inosine, selected as a control agent, on breast cancer cases receiving prophylactic irradiation. Daily dose of 2700 mg of DA-51 and 1800 mg of Inosine were administered orally during a 5 week period of irradiation. The differences between the white blood cell counts, the thrombocyte counts and the percentages of lymphocytes in the DA-51 and the Inosine treated groups were assessed at 1, 3 and 5 weeks by x/sup 2/ and T tests, and the following results are obtained: No significant difference in white blood cell or thrombocyte counts was demonstrated at 1, 3 or 5 weeks between the two groups. The only significant difference noted was in the percentage of lymphocyte at 5 weeks, and the thrombocyte counts at 3 weeks. DNA-spermidine is considered to be an effective drug against radiation-induced leukopenia, comparable to Inosine and without noticeable side effects.
Authors:
Tsuya, A; Kaneta, K; Okawa, T; Nakama, M; [1]  Watari, T
  1. Japanese Foundation for Cancer Research, Tokyo. Hospital
Publication Date:
Aug 01, 1976
Product Type:
Journal Article
Reference Number:
AIX-08-328083; EDB-78-011228
Resource Relation:
Journal Name: Nippon Igaku Hoshasen Gakkai Zasshi; (Japan); Journal Volume: 36:8
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; LEUKOPENIA; RADIOINDUCTION; SPERMIDINE; RADIOSENSITIVITY EFFECTS; AMINES; BLOOD PLATELETS; CARCINOMAS; LYMPHOCYTES; NUCLEIC ACIDS; PATIENTS; RADIOPROTECTIVE SUBSTANCES; RADIOTHERAPY; TIME DEPENDENCE; ANIMAL CELLS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DISEASES; DRUGS; HEMIC DISEASES; LEUKOCYTES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; PATHOLOGICAL CHANGES; RADIOLOGY; RESPONSE MODIFYING FACTORS; SOMATIC CELLS; SYMPTOMS; THERAPY; 560151* - Radiation Effects on Animals- Man
OSTI ID:
7210089
Country of Origin:
Japan
Language:
Japanese
Other Identifying Numbers:
Journal ID: CODEN: NHGZA
Submitting Site:
INIS
Size:
Pages: 702-709
Announcement Date:
Oct 01, 1977

Journal Article:

Citation Formats

Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T. Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation. Japan: N. p., 1976. Web.
Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, & Watari, T. Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation. Japan.
Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T. 1976. "Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation." Japan.
@misc{etde_7210089,
title = {Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation}
author = {Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T}
abstractNote = {DNA-spermidine (DA-51), which has been originally developed by Dr. Sekiguchi et al. as a protective agent against radiation-induced leukopenia, was submitted to clinical trial by the double blind test. The protective effect against radiation-induced leukopenia and side effect of DA-51 were compared with those of Inosine, selected as a control agent, on breast cancer cases receiving prophylactic irradiation. Daily dose of 2700 mg of DA-51 and 1800 mg of Inosine were administered orally during a 5 week period of irradiation. The differences between the white blood cell counts, the thrombocyte counts and the percentages of lymphocytes in the DA-51 and the Inosine treated groups were assessed at 1, 3 and 5 weeks by x/sup 2/ and T tests, and the following results are obtained: No significant difference in white blood cell or thrombocyte counts was demonstrated at 1, 3 or 5 weeks between the two groups. The only significant difference noted was in the percentage of lymphocyte at 5 weeks, and the thrombocyte counts at 3 weeks. DNA-spermidine is considered to be an effective drug against radiation-induced leukopenia, comparable to Inosine and without noticeable side effects.}
journal = {Nippon Igaku Hoshasen Gakkai Zasshi; (Japan)}
volume = {36:8}
journal type = {AC}
place = {Japan}
year = {1976}
month = {Aug}
}